Clinical Trial: Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07845786) titled 'Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)' on Sept. 22.

Brief Summary: The primary purpose of the study is to evaluate the effectiveness of zanzalintinib in combination with pembrolizumab as first-line maintenance therapy in participants with metastatic squamous NSCLC.

Study Start Date: Dec. 15, 2026

Study Type: INTERVENTIONAL

Condition: Squamous Non-Small Cell Lung Cancer (NSCLC)

Intervention: DRUG: Carboplatin

Administered as part of SOC therapy as specified in the treatment arm.

DRUG: Paclitaxel

Administered as part of SOC therapy as specified in...